Day: May 19, 2025

Codere Online will officially sponsor Club de Fútbol Monterrey at the 2025 Club World Cup. Rayados, Codere Online and Puma present the uniform with which the team will commemorate the club’s 80th anniversary.Mexico City/Madrid, May 19, 2025 – (GLOBE NEWSWIRE) Codere Online (Nasdaq: CDRO / CDROW), a leading online gaming operator in Spain and Latin America, has launched the commemorative jersey that will accompany Club de Futbol Monterrey at the 2025 Club World Cup. This special edition kit comes as part of the Club’s 80th Anniversary celebrations. With this sponsorship, the Codere logo will be displayed exclusively on the front of Monterrey Football Club’s jersey during the 32-team tournament. In addition, Codere Online will offer unique and differentiated experiences so all fans can experience the largest-ever Club...

  Bank of Åland PlcChange, Board/Executive Team/AuditorsMay 19, 2025, 17.00 EET Pasi Poikkeus appointed Deputy Head of the Finnish Mainland Business Area Pasi Poikkeus has been appointed Deputy Head of the Finnish Mainland Business Area, thereby also becoming a deputy member of the Executive Team. Poikkeus holds degrees in Master of Social Sciences (econ.) and Executive Master of Business Administration and is Head of the bank’s Private Banking within the Finnish Mainland Business Area. He has been with Bank of Åland since 2023 and will assume his new position immediately. For further information, please contact:Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel. +358 204 291 225Pasi Poikkeus, Head of Private Banking Finland, tel +358 50 358 3000

Brings Proven Commercial Leadership, Reimbursement Expertise, and Global Market Insight to Support Next Phase of Growth Across Medical and Dental Segments ROSELAND, N.J., May 19, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Shanth Thiyagalingam, BMedSc, MMKTG, MBA, has joined its Board of Directors, effective May 14, 2025. Mr. Thiyagalingam brings more than 20 years of global leadership in commercial scaling, product innovation, and strategic execution across the medical device and pharmaceutical industries.Newly appointed board member Shanth Thiyagalingam This appointment further supports Milestone Scientific’s strategy to drive adoption of its CompuFlo® Epidural System, broaden...

The eRead for the future initiative focuses on delivering cutting edge technology that promotes reading for kids BILLERICA, Mass., May 19, 2025 (GLOBE NEWSWIRE) — E Ink (8069.TW), the originator, pioneer, and global commercial leader in ePaper technology, announced today its collaborative donation with MediaTek to the Boys and Girls Clubs of Metro Louisiana as part of E Ink’s eRead for the Future program. E Ink and MediaTek are donating 58 Amazon Kindle Kids eReaders—each Kindle Kids device features an E Ink ePaper display for a comfortable, paper-like reading experience and is powered by MediaTek’s advanced chipset technology. “The donation from E Ink and MediaTek will have a meaningful impact on the children,” said Brandon Smith, Clubs Director of the Boys & Girls Clubs of Metro Louisiana. “Access to books and educational...

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will present at the Biomed Israel 2025 conference, reviewing the Company’s topline Phase 2 results for BX211 in DFO. The conference is being held between May 20 – 22, 2025, in Tel Aviv, Israel. Presentation DetailsOral Presentation Title Precision Phage Therapy for Chronic Diabetic Foot Infections   Session Immunology & Inflammation; Reclaim Top Priorities in BioPharma: Driver...

HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) — Nika Pharmaceuticals, Inc. (OTCQB: NIKA) presents projected revenue for each market with exclusive distribution agreement. NIKA has previously reported an estimated potential €7.9 billion in revenue from its distribution agreement in Nigeria1. With similar contact terms for the UAE, Ukraine, Iraq, Jordan, and Syria, NIKA will receive €1,980 per each set of ITV-1 with two sets necessary for one treatment. Although the UAE, Iraq, Jordan, and Syria have a low combined HIV numbers totaling around 7,100 people2 with a projected revenue of around €28,116,000, AIDS/HIV has become a serious problem in the MENA region due to high mortality associated with the disease3. The ease of use, effectiveness, and affordability of NIKA’s treatment will help alleviate this issue. The war in Ukraine...

ATHENS, Greece, May 19, 2025 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that its financial results for the first quarter ended March 31, 2025 are scheduled to be released before the opening of the U.S. financial markets on Thursday, May 29, 2025. The Company’s management will conduct a conference call and simultaneous Internet webcast to review these results at 9:00 A.M. (Eastern Time) on Thursday, May 29, 2025. Investors may access the webcast by visiting the Company’s website at www.dianashippinginc.com, and clicking on the webcast link. An accompanying investor presentation also will be available via the webcast link and on the Company’s website. The conference call also may be accessed...

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time for the Company, which recently reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D). “Michael is an experienced financial executive who will be instrumental in shaping our strategy and brings robust capital...

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts. SAN FRANCISCO, CALIFORNIA, May 19, 2025 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE® natural killer (NK) cell engager platform, today announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. GT Biopharma’s second-generation...